DCAF12 and HSPA1A May Serve as Potential Diagnostic Biomarkers for Myasthenia Gravis

Figure 6

DIRG validation results. (a) Validation results of The Cancer Genome Atlas dataset. The verification dataset results showed that the expression levels of DCAF12 and HSPA1A in MG samples were significantly decreased compared to those in the normal sample, which was consistent with their expression trends in the GSE85452 dataset. (b) The mRNA expression of DCAF12 and HSPA1A. The RNA expression levels of DCAF12 () and HSPA1A () in PBMCs of MG patients were significantly lower than those of healthy controls. (c) ROC curve analysis of DCAF and HSPA1A. (d) Heatmap of the correlation analyses between expression levels (HSPA1A and DCAF12) and six types of immune cells with significant differences quantified by ssGSEA. The expressions of HSPA1A and DCAF12 were all significantly and positively correlated with four immune cell types, namely, the CD56^bright natural killer cell, immature dendritic cell, effector memory CD8 T cell, and macrophage.

(a)

(b)

(c)

(d)